Home » Newsletters » BioWorld Science

BioWorld Science

March 13, 2017

View Archived Issues

Endocyte to collaborate with Seattle Children's Research Institute in CAR T-cell setting

TiGenix reports topline results from phase I/II trial of AlloCSC-01 in acute myocardial infarction

Zafgen discloses novel MetAP 2 inhibitors

First European approval of new breast cancer indication for Decapeptyl

Galera Labs describes new manganese complex prodrugs

Shanghai Institute Materia Medica divulges pyridazinone compounds for HBV infection

Astellas patents alpha-7 nicotinic receptor positive allosteric modulators

Heptares and Daiichi Sankyo collaborate in pain

GlaxoSmithKline presents new antibacterials

Pituitary homeobox 2, a biomarker of progression in breast cancer

Almac Diagnostics selected by EORTC for molecular profiling of cancer patient samples

Activity seen in phase II study of tipifarnib in HRAS-mutant head and neck cancer

Chinese phase I trial investigates anti-CD22 CAR-T therapy in CD19-refractory or resistant lymphoma

New phase II trial in China explores use of anlotinib for small cell lung cancer

Duchesnay acquires U.S. and Canadian rights to market and distribute Osphena

Microbion initiates phase Ib/IIa study of MBN-101 for moderate to severe diabetic foot infection

TFE3 and SOX11 found as diagnostic markers for solid pseudopapillary neoplasms

AbbVie initiates phase I study of immunotherapy ABBV-927 in advanced solid tumors

Urinary tetranor-PGDM can indicate food allergy reactions in children

Intrexon creates wholly owned subsidiary Precigen

EHD2, a new prognostic marker in papillary thyroid carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...